Skip to main content
Paul Meyers, MD, Pediatric Hematology & Oncology, New York, NY

PaulAMeyersMD

Pediatric Hematology & Oncology New York, NY

Professor of Pediatrics, Cornell University-Weill Medical College

Overview of Dr. Meyers

Dr. Paul Meyers is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 44 years. He also speaks multiple languages, including Spanish and French. He is experienced in osteosarcoma, ewing sarcoma, rhabdomyosarcoma, pediatric sarcomas, and combined modality therapy. He has more than 225 publications and over 20,000 citings.

Education & Training

  • Memorial Hospital
    Memorial Hospital1978 - 1979
  • Sloan-Kettering Institute
    Sloan-Kettering Institute1977 - 1979
  • Cornell Medical Center
    Cornell Medical Center1976 - 1976
  • Mt Sinai Hospital
    Mt Sinai Hospital1974 - 1976
  • Mt Sinai Hospital
    Mt Sinai Hospital1973 - 1974
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1973
  • Brown University
    Brown UniversityAB, Cum laude, 1966 - 1971

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 1974 - 2026
  • NJ State Medical License
    NJ State Medical License 1982 - 2025
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • New York Magazine: Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors Castle Connolly, 2002-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Identification of lactoferrin as the granulocyte-derived inhibitor of colony-stimulating activity production.  
    Broxmeyer HE, Smithyman A, Eger RR, Meyers PA, de Sousa M, J Exp Med. 1978 Oct 1;148(4):1052-67
  • Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera.  
    Winchester RJ, Meyers PA, Broxmeyer HE, Wang CY, Moore MA, Kunkel HG, J Exp Med. 1978 Aug 1;148(2):613-8
  • Characteristics of bone marrow and blood cells in human leukemia that produce leukemia inhibitory activity (LIA).  
    Broxmeyer HE, Ralph P, Margolis V, Nakoinz I, Meyers PA, Kapoor N, and Moore MAS., Leukemia Research 1979; 3:193-203
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Press Mentions

  • Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
    Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual MeetingNovember 14th, 2019
  • Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting
    Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group MeetingNovember 5th, 2019
  • Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma
    Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing SarcomaOctober 8th, 2019

Grant Support

  • Core BNational Cancer Institute2005–2009

Professional Memberships

Other Languages

  • Spanish, French